Articles:

Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides

Sanjeev Shangary, Christopher L. Oliver, Tommy S. Tillman, Michael Cascio, and Daniel E. Johnson
Mol Cancer Ther 2004 3: 1343-1354. [Abstract] [Full Text] [PDF]  

Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-

Ai Shih, Shenli Zhang, H. James Cao, Sarah Boswell, Yun-Hsuan Wu, Heng-Yuan Tang, Michelle R. Lennartz, Faith B. Davis, Paul J. Davis, and Hung-Yun Lin
Mol Cancer Ther 2004 3: 1355-1364. [Abstract] [Full Text] [PDF]  

Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity

Shailaja Kasibhatla, Henriette Gourdeau, Karen Meerovitch, John Drewe, Sanjeeva Reddy, Ling Qiu, Hong Zhang, Frederick Bergeron, David Bouffard, Quan Yang, John Herich, Serge Lamothe, Sui Xiong Cai, and Ben Tseng
Mol Cancer Ther 2004 3: 1365-1374. [Abstract] [Full Text] [PDF]  

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Henriette Gourdeau, Lorraine Leblond, Bettina Hamelin, Clemence Desputeau, Kelly Dong, Irenej Kianicka, Dominique Custeau, Chantal Boudreau, Lilianne Geerts, Sui-Xiong Cai, John Drewe, Denis Labrecque, Shailaja Kasibhatla, and Ben Tseng
Mol Cancer Ther 2004 3: 1375-1384. [Abstract] [Full Text] [PDF]  

Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells

Huiyun Liang, Richard A. Salinas, Belinda Z. Leal, Teresa Kosakowska-Cholody, Christopher J. Michejda, Stephen J. Waters, Terence S. Herman, Jan M. Woynarowski, and Barbara A. Woynarowska
Mol Cancer Ther 2004 3: 1385-1396. [Abstract] [Full Text] [PDF]  

The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells

Seiji Doi, Hiroshi Soda, Mikio Oka, Junji Tsurutani, Takeshi Kitazaki, Yoichi Nakamura, Minoru Fukuda, Yasuaki Yamada, Shimeru Kamihira, and Shigeru Kohno
Mol Cancer Ther 2004 3: 1397-1402. [Abstract] [Full Text] [PDF]  

Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues

Alex V. Trevino, Barbara A. Woynarowska, Terence S. Herman, Waldemar Priebe, and Jan M. Woynarowski
Mol Cancer Ther 2004 3: 1403-1410. [Abstract] [Full Text] [PDF]  

8-Amino-adenosine is a potential therapeutic agent for multiple myeloma

Nancy L. Krett, Katharine M. Davies, Mary Ayres, Chunguang Ma, Chadi Nabhan, Varsha Gandhi, and Steven T. Rosen
Mol Cancer Ther 2004 3: 1411-1420. [Abstract] [Full Text] [PDF]  

Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines

Basil F. El-Rayes, Shadan Ali, Fazlul H. Sarkar, and Philip A. Philip
Mol Cancer Ther 2004 3: 1421-1426. [Abstract] [Full Text] [PDF]  

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, Patricia J. Harvey, Paul R. Keller, William L. Elliott, MaryAnne Meade, Erin Trachet, Mudher Albassam, XianXian Zheng, Wilbur R. Leopold, Nancy K. Pryer, and Peter L. Toogood
Mol Cancer Ther 2004 3: 1427-1438. [Abstract] [Full Text] [PDF]  

Screening a combinatorial peptide library to develop a human glandular kallikrein 2–activated prodrug as targeted therapy for prostate cancer

Samuel Janssen, Carsten M. Jakobsen, D. Marc Rosen, Rebecca M. Ricklis, Ulrich Reineke, Soeren B. Christensen, Hans Lilja, and Samuel R. Denmeade
Mol Cancer Ther 2004 3: 1439-1450. [Abstract] [Full Text] [PDF]  

Secretory phospholipase A₂ as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids

Simon S. Jensen, Thomas L. Andresen, Jesper Davidsen, Pernille Høyrup, Steven D. Shnyder, Michael C. Bibby, Jason H. Gill, and Kent Jørgensen
Mol Cancer Ther 2004 3: 1451-1458. [Abstract] [Full Text] [PDF]  

Modulation of p53 in 7,12-dimethylbenz[a]anthracene–induced skin tumors by diallyl sulfide in Swiss albino mice

Annu Arora, Imtiaz A. Siddiqui, and Yogeshwer Shukla
Mol Cancer Ther 2004 3: 1459-1466. [Abstract] [Full Text] [PDF]  

Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival

Jane Renshaw, Rosanne M. Orr, Michael I. Walton, Robert te Poele, Richard D. Williams, Edward V. Wancewicz, Brett P. Monia, Paul Workman, and Kathryn Pritchard-Jones
Mol Cancer Ther 2004 3: 1467-1484. [Abstract] [Full Text] [PDF]  

Minireview:

The role of nuclear Y-box binding protein 1 as a global marker in drug resistance

Michihiko Kuwano, Yoshinao Oda, Hiroto Izumi, Song-Ju Yang, Takeshi Uchiumi, Yukihide Iwamoto, Masakazu Toi, Teruhiko Fujii, Hideaki Yamana, Hisafumi Kinoshita, Toshiharu Kamura, Masazumi Tsuneyoshi, Kosei Yasumoto, and Kimitoshi Kohno
Mol Cancer Ther 2004 3: 1485-1492. [Abstract] [Full Text] [PDF]  

Biological impediments to monoclonal antibody–based cancer immunotherapy

Jason Christiansen and Ayyappan K. Rajasekaran
Mol Cancer Ther 2004 3: 1493-1501. [Abstract] [Full Text] [PDF]  

Letters to the Editor:

Cytochrome P450 enzymes and tumor therapy

Matthias Löhr, Morag C.E. McFadyen, Graeme I. Murray, and William T. Melvin
Mol Cancer Ther 2004 3: 1503-1504. [Full Text] [PDF]  

To see an article, click its [Full Text] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.